Abstract:Background: MicroRNA-155-5p (miR-155-5p) has been reported to play an oncogenic role in different human malignancies; however, its role in Wilms tumor (WT) remains unclear. Methods: Differentially expressed miRNAs (DE-miRNAs) and mRNAs (DEGs) in WT blood and tissues were identified by using miRNA microarray and RNA-sequencing. Bioinformatics prediction and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were used to predict the potential functions of DE-miRNAs. DE-miRNAs and DEGs in WT obtained from Gene Expression Omnibus (GEO) and Therapeutically Applicable Research to Generate Effective Treatments (TARGET) were identified by using the "edgeR" package. RT-qPCR was used to explore miR-155-5p and IGF2 expression and their clinical significance in WT specimens. A rhabdoid cell line (G401) and Ewing sarcoma cell line (SK-NEP-1) were used. Immunohistochemical staining, western blotting and dual-luciferase reporter assays were performed to study the mechanisms involved. The CCK-8, flow cytometry, wound healing and transwell assays were performed to identify the effects of miR-155-5p and IGF2 knockdown on cell proliferation, apoptosis, migration and invasion, respectively. Results: MiR-155-5p was downregulated in both blood and tissues from WT patients who did not receive chemotherapy before surgery but was upregulated in tissues from WT patients who had received chemotherapy before surgery. IGF2, PI3K, AKT and mTOR were found to be upregulated in WT tissues. Additionally, miR-155-5p and IGF2 were significantly correlated with TNM stage and lymphatic metastasis in WT patients. Molecular mechanism exploration indicated that IGF2 was downregulated by miR-155-5p via direct binding to its 3' untranslated region in cell lines. Furthermore, IGF2, PI3K, AKT and mTOR expression was inversely correlated with miR-155-5p expression, and PI3K, AKT and mTOR expression was positively correlated with IGF2 expression in cell culture. Functional studies demonstrated that miR-155-5p upregulation and IGF2 knockdown suppressed cell proliferation, migration and invasion and induced cell apoptosis. Moreover, the tumor-suppressing effects of miR-155-5p in cells were abrogated by miR-155-5p inhibitor treatment. Conclusions: Taken together, these findings suggest that miR-155-5p functions as a tumor suppressor in WT through inactivating the PI3K/AKT/mTOR signaling pathway by directly targeting IGF2. Thus, miR-155-5p might be a novel therapeutic target for WT.

UNC13B regulates the sensitivity of Wilms' tumor cells to doxorubicin by modulating lysosomes

Mir-223/Fbw7 Axis Regulates Doxorubicin Sensitivity Through Epithelial Mesenchymal Transition in Non-Small Cell Lung Cancer.

High Expression of UNC5B Enhances Tumor Proliferation, Increases Metastasis, and Worsens Prognosis in Breast Cancer.

Investigating the Dysfunctional Pathogenesis of Wilms' Tumor Through a Multidimensional Integration Strategy.

MiR-22-3p Regulates the Proliferation and Invasion of Wilms' Tumor Cells by Targeting AKT3.

Silencing of Lncrna MEG8 Represses the Viability, Migration, and Invasion of Wilms’ Tumor Cells Through Mediating Mir-23A-3p/crk Axis

Tumor Suppressive Role of MUC6 in Wilms Tumor Via Autophagy-Dependent Β-Catenin Degradation

Multidimensional Transcriptomics Unveils RNF34 as a Prognostic Biomarker and Potential Indicator of Chemotherapy Sensitivity in Wilms' Tumour

Rna-Sequencing, Connectivity Mapping, And Molecular Docking To Investigate Ligand-Protein Binding For Potential Drug Candidates For The Treatment Of Wilms Tumor

Actinomycin D and bortezomib disrupt protein homeostasis in Wilms tumor

CCNB1 is a Novel Prognostic Biomarker and Promotes Proliferation, Migration and Invasion in Wilms Tumor.

[Expression of miR-155-5p in Wilms tumor and its regulatory role in proliferation, migration and apoptosis of Wilms tumor cells in vitro].

The synergistic effects of anoikis-related genes and EMT-related genes in the prognostic prediction of Wilms tumor

PD-L1 expression is mediated by microRNA processing, Wnt/β-catenin signaling, and chemotherapy in Wilms tumor

The Expression and Potential Role of Tubulin Alpha 1b in Wilms’ Tumor

Modeling high-risk Wilms tumors enables the discovery of therapeutic vulnerability

KHSRP modulated cell proliferation and cell cycle via regulating PPP2CA and p27 expression in Wilms tumor

HnRNPL Promotes Wilms Tumor Progression by Regulating the P53 and Bcl2 Pathways.

Comprehensive Analysis of a Long Noncoding RNA-Associated Competing Endogenous RNA Network in Wilms Tumor

Wilms’ Tumor 1-Associated Protein Contributes to Chemo-Resistance to Cisplatin Through the Wnt/β-Catenin Pathway in Endometrial Cancer

MiR-155-5p Exerts Tumor-Suppressing Functions in Wilms Tumor by Targeting IGF2 Via the PI3K Signaling Pathway.